Circulating tumor cells versus imaging - Predicting overall survival in metastatic breast cancer

Clinical Cancer Research

Volumn 12, Issue 21, 2006, Pages 6403-6409

  Budd, G Thomas ^a   Cristofanilli, Massimo ^b   Ellis, Mathew J ^c   Stopeck, Allison ^d   Borden, Ernest ^a   Miller, M Craig ^e   Matera, Jeri ^e   Repollet, Madeline ^e   Doyle, Gerald V ^e   Terstappen, Leon W M M ^e   Hayes, Daniel F ^f  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c WASHINGTON UNIVERSITY   (United States)

^d UNIVERSITY OF ARIZONA   (United States)

^e Immunicon Corporation   (United States)

^f UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER REGRESSION; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; HUMAN; IMAGING; MAJOR CLINICAL STUDY; METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RADIOGRAPHY; TUMOR CELL;

BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; OBSERVER VARIATION; PROGNOSIS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 33751272999     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-1769     Document Type: Article

References (21)

1. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
2. Ellis MJ, Hayes DF, Lippman ME. Treatment of metastatic breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, editors. Diseases of the breast. 2nd ed. Philadelphia (PA): Lippincott; 1999. p. 749-97.
3. Allard WJ, Matera J, Miller MC. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Clin Cancer Res 2004;10:6897-904.
4. Cristofanilli M, Budd GT, Ellis M, et al. Circulating tumor cells, disease progression, and survival in metastatic breast cancer. N Engl J Med 2004;351:781-91.
5. Cristofanilli M, Hayes DF, Budd GT, et al. Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer. J Clin Oncol 2005;23:1420-30.
6. Miller AB, Hoogstraten G, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
7. Rao CG, Chianese D, Doyle GV, et al. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors, Int J Oncol 2005;27:49-57.
8. Kagan M, Howard D, Bendele T, et al. A sample preparation and analysis system for identification of circulating tumor cells. J Clin Lig Assay 2002;25:104-10.
9. Kagan M, Howard D, Bendele T, Rao C, Terstappen LWMM. Circulating tumor cells as cancer markers, a sample preparation and analysis system. In: Diamandis EP, Fritsche HA, Lilja H, Chan DW, Schwartz M, editors. Tumor markers: physiology, pathobiology, technology, and clinical applications. Washington (DC): AACC Press; 2002. p. 495-8.
10. Thiesse P, Ollivier L, Di Stefano-Louineau D, et al. Response rate accuracy in oncology trials: reasons for interobserver variability. Groupe Francais d'Immunotherapie of the Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 1997;15:3507-14.
11. Erasmus JJ, Gladish GW, Broemeling L, et al. Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response. J Clin Oncol 2003;21:2574-82.
12. Paterson AH, Cyr M, Szafran O, Lees AW, Hanson J. Response to treatment and its influence on survival in metastatic breast cancer. Am J Clin Oncol 1985;8:283-92.
13. Robertson J. Prognostic and response markers in the management of breast cancer. Cancer Treat Rev 1997;23 Suppl 1:341-8.
14. Outcomes Working Group, Health Services Research Committee, American Society of Clinical Oncology. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671-9.
15. Nottage M, Siu LL. Principles of clinical trial design. J Clin Oncol 2002;20:42-6S.
16. Pazdur R. Response rates, survival, and chemotherapy trials. J Natl Cancer Inst 2000;92:1552-3.
17. Colomer R, Ruibal A, Salvador L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989;64:1674-81.
18. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol 1983;1:710-9.
19. Anderson JR. Commonly misused approaches to the analysis of cancer clinical trials. In: Crowley J, editor. Handbook of statistics in clinical oncology. New York: Marcel Dekker, Inc.; 2001. p. 491-502.
20. Budd GT, Cristofanilli M, Ellis MJ, et al. Monitoring circulating tumor cells (CTC) in non-measurable metastatic breast cancer (MBC). Proc Annu Meet Am Soc Clin Oncol 2005;24:A503.
21. Simon R. Clinical trials in cancer. In: Devita VT, Jr., Hellman S, Rosenberg SA, editors. Cancer: principles and practice of oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 521-38.